世界中の市場調査レポートを販売!当社に無いレポートもお探しします。

レポートナンバー 0000038611

CAR-T療法市場レポート2024-2034

Visiongain

CAR-T Therapy Market Report 2024-2034

発刊日 2024/06/27

言語英語

体裁PDF/337ページ

ライセンス/価格337ページ

0000038611

Single - 1 Year License
(Team License - Up to 6 Users) - 1 Year License
Site
Enterprise

※ご請求は、お申込日のTTSレートで円換算し、消費税を加えた金額になります。
※シングルユーザーライセンスのレポートは印刷不可、およびライセンス期間は1年となります。
※印刷可能のレポートをご希望の場合は、デパートメントライセンス(ライセンス期間1年、ユーザー数6人)をご検討ください。
※詳しくはお問い合わせください。

無料サンプル

  • サンプルはお問い合わせください。

レポート概要

適応症別 (びまん性大細胞型B細胞リンパ腫 (DLBCL)、急性リンパ芽球性白血病 (ALL)、濾胞性リンパ腫、多発性骨髄腫 (MM)、その他)、タイプ別 (Abecma、Yescarta、Kymriah、Tecartus、その他)、標的抗原別 (CD19/CD22、BCMA、その他)、患者別 (小児、成人、高齢者)、エンドユーザー別 (病院、専門クリニック、その他)、地域別および主要国内市場分析および主要企業の分析

新興市場におけるCAR-T細胞療法の採用が市場成長を牽引

先進国と比較すると、新興市場におけるCAR-T細胞療法の採用はやや低迷しています。これは主に、これらの治療法には多額の費用がかかり、必要なインフラと専門知識を確立するのは簡単ではないためです。しかし、今後数年間で、多くの変数が新興国でのCAR-T細胞療法の使用の増加に寄与する可能性があります。人口の高齢化、都市化、不健康なライフスタイルはすべて、中国、インド、ブラジルを含むいくつかの新興経済国におけるがん発生率の顕著な増加に寄与しています。CAR-T細胞療法などの先進的ながん治療は、疾病の負担増によってますます必要とされています。

新興国では、バイオ医薬品企業が現地の企業や研究機関と協業し、パートナーシップを結び、CAR-T細胞治療薬の開発、生産、流通を促進しています。これらのパートナーシップは、管理上および法律上の問題の解決に役立ちます。CAR-T細胞治療薬の研究と承認を促進するために、中国やインドなどのいくつかの新興市場では、規制の枠組みとガイドラインが導入されています。これは、投資と取り込みの増加につながる可能性があります。

レポート詳細

目次

1 Report Overview
1.1 Objectives of the Study
1.2 Introduction to CAR-T Therapy Market
1.3 What This Report Delivers
1.4 Why You Should Read This Report
1.5 Key Questions Answered by This Analytical Report
1.6 Who is This Report for?
1.7 Methodology
1.7.1 Market Definitions
1.7.2 Market Evaluation & Forecasting Methodology
1.7.3 Data Validation
1.7.3.1 Primary Research
1.7.3.2 Secondary Research
1.8 Frequently Asked Questions (FAQs)
1.9 Associated Visiongain Reports
1.10 About Visiongain

2 Executive Summary

3 Market Overview
3.1 Key Findings
3.2 Market Dynamics
3.3 Impact Analysis
3.3.1 Market Driving Factors
3.3.1.1 Increasing Cancer Incidence
3.3.1.2 Increasing Research and Development to Enhance Treatment with CAR-T Cell Therapy
3.3.1.3 Growing Ongoing Clinical Trials and Regulatory Approvals
3.3.2 Market Restraining Factors
3.3.2.1 High Cost of CAR-T Cell Therapy
3.3.2.2 Safety Concerns Remain a Critical Aspect Influencing the CAR-T Cell Therapy
3.3.3 Market Opportunities
3.3.3.1 Expanding Target Indications
3.3.3.2 Increasing Adoption of CAR-T Cell Therapy in Emerging Markets
3.4 Supply Chain Analysis
3.5 Regulatory Framework
3.6 COVID-19 Impact Analysis
3.7 Porter Analysis
3.8 PEST Analysis
3.8.1 Political Factors:
3.8.2 Economic Factors:
3.8.3 Social Factors:
3.8.4 Technological Factors:

4 CAR-T Therapy Market Analysis by Target Antigens
4.1 Key Findings
4.2 Target Antigens Segment: Market Attractiveness Index
4.3 CAR-T Therapy Market Size Estimation and Forecast by Target Antigens
4.4 CD19/CD22
4.4.1 Market Size by Region, 2024-2034 (US$ Million)
4.4.2 Market Share by Region, 2024 & 2034 (%)
4.5 BCMA
4.5.1 Market Size by Region, 2024-2034 (US$ Million)
4.5.2 Market Share by Region, 2024 & 2034 (%)
4.6 Others
4.6.1 Market Size by Region, 2024-2034 (US$ Million)
4.6.2 Market Share by Region, 2024 & 2034 (%)

5 CAR-T Therapy Market Analysis by Type
5.1 Key Findings
5.2 Type Segment: Market Attractiveness Index
5.3 CAR-T Therapy Market Size Estimation and Forecast by Type
5.4 Abecma
5.4.1 Market Size by Region, 2024-2034 (US$ Million)
5.4.2 Market Share by Region, 2024 & 2034 (%)
5.5 Yescarta
5.5.1 Market Size by Region, 2024-2034 (US$ Million)
5.5.2 Market Share by Region, 2024 & 2034 (%)
5.6 Kymriah
5.6.1 Market Size by Region, 2024-2034 (US$ Million)
5.6.2 Market Share by Region, 2024 & 2034 (%)
5.7 Tecartus
5.7.1 Market Size by Region, 2024-2034 (US$ Million)
5.7.2 Market Share by Region, 2024 & 2034 (%)
5.8 Other Types
5.8.1 Market Size by Region, 2024-2034 (US$ Million)
5.8.2 Market Share by Region, 2024 & 2034 (%)

6 CAR-T Therapy Market Analysis by Indication
6.1 Key Findings
6.2 Indication Segment: Market Attractiveness Index
6.3 CAR-T Therapy Market Size Estimation and Forecast by Indication
6.4 Diffuse Large B-Cell Lymphoma (DLBCL)
6.4.1 Market Size by Region, 2024-2034 (US$ Million)
6.4.2 Market Share by Region, 2024 & 2034 (%)
6.5 Acute Lymphoblastic Leukaemia (ALL)
6.5.1 Market Size by Region, 2024-2034 (US$ Million)
6.5.2 Market Share by Region, 2024 & 2034 (%)
6.6 Follicular Lymphoma
6.6.1 Market Size by Region, 2024-2034 (US$ Million)
6.6.2 Market Share by Region, 2024 & 2034 (%)
6.7 Multiple Myeloma (MM)
6.7.1 Market Size by Region, 2024-2034 (US$ Million)
6.7.2 Market Share by Region, 2024 & 2034 (%)
6.8 Other Indication
6.8.1 Market Size by Region, 2024-2034 (US$ Million)
6.8.2 Market Share by Region, 2024 & 2034 (%)

7 CAR-T Therapy Market Analysis by End-users
7.1 Key Findings
7.2 End-users Segment: Market Attractiveness Index
7.3 CAR-T Therapy Market Size Estimation and Forecast by End-users
7.4 Hospitals
7.4.1 Market Size by Region, 2024-2034 (US$ Million)
7.4.2 Market Share by Region, 2024 & 2034 (%)
7.5 Specialty Clinics
7.5.1 Market Size by Region, 2024-2034 (US$ Million)
7.5.2 Market Share by Region, 2024 & 2034 (%)
7.6 Other End-users
7.6.1 Market Size by Region, 2024-2034 (US$ Million)
7.6.2 Market Share by Region, 2024 & 2034 (%)

8 CAR-T Therapy Market Analysis by Patient
8.1 Key Findings
8.2 Patient Segment: Market Attractiveness Index
8.3 CAR-T Therapy Market Size Estimation and Forecast by Patient
8.4 Children
8.4.1 Market Size by Region, 2024-2034 (US$ Million)
8.4.2 Market Share by Region, 2024 & 2034 (%)
8.5 Adults
8.5.1 Market Size by Region, 2024-2034 (US$ Million)
8.5.2 Market Share by Region, 2024 & 2034 (%)
8.6 Seniors
8.6.1 Market Size by Region, 2024-2034 (US$ Million)
8.6.2 Market Share by Region, 2024 & 2034 (%)

9 CAR-T Therapy Market Analysis by Region
9.1 Key Findings
9.2 Regional Market Size Estimation and Forecast

10 North America CAR-T Therapy Market Analysis
10.1 Key Findings
10.2 North America CAR-T Therapy Market Attractiveness Index
10.3 North America CAR-T Therapy Market by Country, 2024, 2029 & 2034 (US$ Million)
10.4 North America CAR-T Therapy Market Size Estimation and Forecast by Country
10.5 North America CAR-T Therapy Market Size Estimation and Forecast by Target Antigens
10.6 North America CAR-T Therapy Market Size Estimation and Forecast by Type
10.7 North America CAR-T Therapy Market Size Estimation and Forecast by Indication
10.8 North America CAR-T Therapy Market Size Estimation and Forecast by End-users
10.9 North America CAR-T Therapy Market Size Estimation and Forecast by Patients
10.10 U.S. CAR-T Therapy Market Analysis
10.11 Canada CAR-T Therapy Market Analysis

11 Europe CAR-T Therapy Market Analysis
11.1 Key Findings
11.2 Europe CAR-T Therapy Market Attractiveness Index
11.3 Europe CAR-T Therapy Market by Country, 2024, 2029 & 2034 (US$ Million)
11.4 Europe CAR-T Therapy Market Size Estimation and Forecast by Country
11.5 Europe CAR-T Therapy Market Size Estimation and Forecast by Target Antigens
11.6 Europe CAR-T Therapy Market Size Estimation and Forecast by Type
11.7 Europe CAR-T Therapy Market Size Estimation and Forecast by Indication
11.8 Europe CAR-T Therapy Market Size Estimation and Forecast by End-users
11.9 Europe CAR-T Therapy Market Size Estimation and Forecast by Patients
11.10 Germany CAR-T Therapy Market Analysis
11.11 UK CAR-T Therapy Market Analysis
11.12 France CAR-T Therapy Market Analysis
11.13 Italy CAR-T Therapy Market Analysis
11.14 Spain CAR-T Therapy Market Analysis
11.15 Rest of Europe CAR-T Therapy Market Analysis

12 Asia Pacific CAR-T Therapy Market Analysis
12.1 Key Findings
12.2 Asia Pacific CAR-T Therapy Market Attractiveness Index
12.3 Asia Pacific CAR-T Therapy Market by Country, 2024, 2029 & 2034 (US$ Million)
12.4 Asia Pacific CAR-T Therapy Market Size Estimation and Forecast by Country
12.5 Asia Pacific CAR-T Therapy Market Size Estimation and Forecast by Target Antigens
12.6 Asia Pacific CAR-T Therapy Market Size Estimation and Forecast by Type
12.7 Asia Pacific CAR-T Therapy Market Size Estimation and Forecast by Indication
12.8 Asia Pacific CAR-T Therapy Market Size Estimation and Forecast by End-users
12.9 Asia Pacific CAR-T Therapy Market Size Estimation and Forecast by Patients
12.10 China CAR-T Therapy Market Analysis
12.11 Japan CAR-T Therapy Market Analysis
12.12 Singapore CAR-T Therapy Market Analysis
12.13 Australia CAR-T Therapy Market Analysis
12.14 South Korea CAR-T Therapy Market Analysis
12.15 Rest of Asia Pacific CAR-T Therapy Market Analysis

13 Latin America CAR-T Therapy Market Analysis
13.1 Key Findings
13.2 Latin America CAR-T Therapy Market Attractiveness Index
13.3 Latin America CAR-T Therapy Market by Country, 2024, 2029 & 2034 (US$ Million)
13.4 Latin America CAR-T Therapy Market Size Estimation and Forecast by Country
13.5 Latin America CAR-T Therapy Market Size Estimation and Forecast by Target Antigens
13.6 Latin America CAR-T Therapy Market Size Estimation and Forecast by Type
13.7 Latin America CAR-T Therapy Market Size Estimation and Forecast by Indication
13.8 Latin America CAR-T Therapy Market Size Estimation and Forecast by End-users
13.9 Latin America CAR-T Therapy Market Size Estimation and Forecast by Patients
13.10 Brazil CAR-T Therapy Market Analysis
13.11 Mexico CAR-T Therapy Market Analysis
13.12 Rest of Latin America CAR-T Therapy Market Analysis

14 MEA CAR-T Therapy Market Analysis
14.1 Key Findings
14.2 MEA CAR-T Therapy Market Attractiveness Index
14.3 MEA CAR-T Therapy Market by Country, 2024, 2029 & 2034 (US$ Million)
14.4 MEA CAR-T Therapy Market Size Estimation and Forecast by Country
14.5 MEA CAR-T Therapy Market Size Estimation and Forecast by Target Antigens
14.6 MEA CAR-T Therapy Market Size Estimation and Forecast by Type
14.7 MEA CAR-T Therapy Market Size Estimation and Forecast by Indication
14.8 MEA CAR-T Therapy Market Size Estimation and Forecast by End-users
14.9 MEA CAR-T Therapy Market Size Estimation and Forecast by Patients
14.10 Israel CAR-T Therapy Market Analysis
14.11 GCC CAR-T Therapy Market Analysis
14.12 Rest of MEA CAR-T Therapy Market Analysis

15 Company Profiles
15.1 Competitive Landscape, 2023
15.2 Pipeline analysis
15.3 Strategic Outlook
15.4 Gilead Sciences Inc.
15.4.1 Company Snapshot
15.4.2 Company Overview
15.4.3 Financial Analysis
15.4.3.1 Net Revenue, 2018-2023
15.4.3.2 R&D, 2018-2023
15.4.3.3 Regional Market Shares, 2023
15.4.4 Product Benchmarking
15.4.5 Strategic Outlook
15.4.6 SWOT Analysis
15.5 Novartis AG
15.5.1 Company Snapshot
15.5.2 Company Overview
15.5.3 Financial Analysis
15.5.3.1 Net Revenue, 2018-2023
15.5.3.2 R&D, 2018-2023
15.5.3.3 Regional Market Shares, 2023
15.5.4 Product Benchmarking
15.5.5 Strategic Outlook
15.5.6 SWOT Analysis
15.6 Bristol Myers Squibb
15.6.1 Company Snapshot
15.6.2 Company Overview
15.6.3 Financial Analysis
15.6.3.1 Net Revenue, 2018-2023
15.6.3.2 R&D, 2018-2023
15.6.3.3 Regional Market Shares, 2023
15.6.4 Product Benchmarking
15.6.5 Strategic Outlook
15.6.6 SWOT Analysis
15.7 Johnson & Johnson Services, Inc.
15.7.1 Company Snapshot
15.7.2 Company Overview
15.7.3 Financial Analysis
15.7.3.1 Net Revenue, 2017-2022
15.7.3.2 R&D, 2017-2022
15.7.3.3 Regional Market Shares, 2022
15.7.4 Product Benchmarking
15.7.5 SWOT Analysis
15.8 AbbVie Inc.
15.8.1 Company Snapshot
15.8.2 Company Overview
15.8.3 Financial Analysis
15.8.3.1 Net Revenue, 2018-2023
15.8.3.2 R&D, 2018-2023
15.8.3.3 Regional Market Shares, 2023
15.8.4 Product Benchmarking
15.8.5 Strategic Outlook
15.9 Amgen Inc.
15.9.1 Company Snapshot
15.9.2 Company Overview
15.9.3 Financial Analysis
15.9.3.1 Net Revenue, 2018-2023
15.9.3.2 R&D, 2018-2023
15.9.3.3 Regional Market Shares, 2023
15.9.4 Product Benchmarking
15.10 BioNTech S.E.
15.10.1 Company Snapshot
15.10.2 Company Overview
15.10.3 Financial Analysis
15.10.3.1 Net Revenue, 2018-2023
15.10.3.2 R&D, 2018-2023
15.10.4 Product Benchmarking
15.11 Bluebird bio, Inc.
15.11.1 Company Snapshot
15.11.2 Company Overview
15.11.3 Financial Analysis
15.11.3.1 Net Revenue, 2017-2022
15.11.3.2 R&D, 2017-2022
15.11.4 Product Benchmarking
15.12 Caribou Biosciences Inc.
15.12.1 Company Snapshot
15.12.2 Company Overview
15.12.3 Financial Analysis
15.12.3.1 Net Revenue, 2019-2023
15.12.3.2 R&D, 2019-2023
15.12.4 Product Benchmarking
15.12.5 Strategic Outlook
15.13 GSK plc
15.13.1 Company Snapshot
15.13.2 Company Overview
15.13.3 Financial Analysis
15.13.3.1 Net Revenue, 2018-2023
15.13.3.2 R&D, 2018-2023
15.13.3.3 Regional Market Shares, 2023
15.13.4 Product Benchmarking
15.14 CARsgen Therapeutics Holdings Limited
15.14.1 Company Snapshot
15.14.2 Company Overview
15.14.3 Pipeline Product Benchmarking
15.14.4 Strategic Outlook
15.15 Pfizer Inc.
15.15.1 Company Snapshot
15.15.2 Company Overview
15.15.3 Financial Analysis
15.15.3.1 Net Revenue, 2018-2023
15.15.3.2 R&D, 2018-2023
15.15.3.3 Regional Market Shares, 2023
15.15.4 Pipeline Product Benchmarking
15.15.5 Strategic Outlook
15.16 Autolus Therapeutics
15.16.1 Company Snapshot
15.16.2 Company Overview
15.16.3 Pipeline Product Benchmarking
15.16.4 Strategic Outlook
15.17 Intellia Therapeutics
15.17.1 Company Snapshot
15.17.2 Company Overview
15.17.3 Pipeline Product Benchmarking
15.17.4 Strategic Outlook
15.18 2seventy bio, Inc.
15.18.1 Company Snapshot
15.18.2 Company Overview
15.18.3 Pipeline Product Benchmarking
15.18.4 Strategic Outlook

16 Conclusion and Recommendations
16.1 Concluding Remarks from Visiongain
16.2 Recommendations for Market Players

List of Tables
Table 1 CAR-T Therapy Market Snapshot, 2024 & 2034 (US$ Million, AGR %)
Table 2 Companion Diagnostic Market Forecast by Target Antigens, 2024-2034 (US$ Million, CAGR %, AGR %)
Table 3 CD19/CD22 Segment Market Forecast by Region, 2024-2034 (US$ Million, AGR %, CAGR %)
Table 4 BCMA Segment Market Forecast by Region, 2024-2034 (US$ Million, AGR %, CAGR %)
Table 5 Others Segment Market Forecast by Region, 2024-2034 (US$ Million, AGR %, CAGR %)
Table 6 Companion Diagnostic Market Forecast by Type, 2024-2034 (US$ Million, CAGR %, AGR %)
Table 7 Abecma Segment Market Forecast by Region, 2024-2034 (US$ Million, AGR %, CAGR %)
Table 8 Yescarta Segment Market Forecast by Region, 2024-2034 (US$ Million, AGR %, CAGR %)
Table 9 Kymriah Segment Market Forecast by Region, 2024-2034 (US$ Million, AGR %, CAGR %)
Table 10 Tecartus Segment Market Forecast by Region, 2024-2034 (US$ Million, AGR %, CAGR %)
Table 11 Other Types Segment Market Forecast by Region, 2024-2034 (US$ Million, AGR %, CAGR %)
Table 12 Companion Diagnostic Market Forecast by Indication, 2024-2034 (US$ Million, CAGR %, AGR %)
Table 13 Diffuse Large B-Cell Lymphoma (DLBCL) Segment Market Forecast by Region, 2024-2034 (US$ Million, AGR %, CAGR %)
Table 14 Acute Lymphoblastic Leukaemia (ALL) Segment Market Forecast by Region, 2024-2034 (US$ Million, AGR %, CAGR %)
Table 15 Follicular Lymphoma Segment Market Forecast by Region, 2024-2034 (US$ Million, AGR %, CAGR %)
Table 16 Multiple Myeloma (MM) Segment Market Forecast by Region, 2024-2034 (US$ Million, AGR %, CAGR %)
Table 17 Other Indication Segment Market Forecast by Region, 2024-2034 (US$ Million, AGR %, CAGR %)
Table 18 CAR-T Therapy Market Forecast by End-users, 2024-2034 (US$ Million, CAGR %, AGR %)
Table 19 Hospitals Segment Market Forecast by Region, 2024-2034 (US$ Million, AGR %, CAGR %)
Table 20 Specialty Clinics Segment Market Forecast by Region, 2024-2034 (US$ Million, AGR %, CAGR %)
Table 21 Other End-users Segment Market Forecast by Region, 2024-2034 (US$ Million, AGR %, CAGR %)
Table 22 CAR-T Therapy Market Forecast by Patient, 2024-2034 (US$ Million, CAGR %, AGR %)
Table 23 Children Segment Market Forecast by Region, 2024-2034 (US$ Million, AGR %, CAGR %)
Table 24 Adults Segment Market Forecast by Region, 2024-2034 (US$ Million, AGR %, CAGR %)
Table 25 Seniors Segment Market Forecast by Region, 2024-2034 (US$ Million, AGR %, CAGR %)
Table 26 CAR-T Therapy Market Forecast by Region, 2024-2034 (US$ Million, AGR %, CAGR %)
Table 27 North America CAR-T Therapy Market Forecast by Country, 2024-2034 (US$ Million, AGR %)
Table 28 North America CAR-T Therapy Market Forecast by Target Antigens, 2024-2034 (US$ Million, AGR %)
Table 29 North America CAR-T Therapy Market Forecast by Type, 2024-2034 (US$ Million, AGR %)
Table 30 North America CAR-T Therapy Market Forecast by Indication, 2024-2034 (US$ Million, AGR %)
Table 31 North America CAR-T Therapy Market Forecast by End-users, 2024-2034 (US$ Million, AGR %)
Table 32 North America CAR-T Therapy Market Forecast by Patients, 2024-2034 (US$ Million, AGR %)
Table 33 U.S. CAR-T Therapy Market Forecast, 2024-2034 (US$ Million, AGR %, CAGR %)
Table 34 Canada CAR-T Therapy Market Forecast, 2024-2034 (US$ Million, AGR %, CAGR %)
Table 35 Europe CAR-T Therapy Market Forecast by Country, 2024-2034 (US$ Million, AGR %)
Table 36 Europe CAR-T Therapy Market Forecast by Target Antigens, 2024-2034 (US$ Million, AGR %)
Table 37 Europe CAR-T Therapy Market Forecast by Type, 2024-2034 (US$ Million, AGR %)
Table 38 Europe CAR-T Therapy Market Forecast by Indication, 2024-2034 (US$ Million, AGR %)
Table 39 Europe CAR-T Therapy Market Forecast by End-users, 2024-2034 (US$ Million, AGR %)
Table 40 Europe CAR-T Therapy Market Forecast by Patients, 2024-2034 (US$ Million, AGR %)
Table 41 Germany CAR-T Therapy Market Forecast, 2024-2034 (US$ Million, AGR %, CAGR %)
Table 42 UK CAR-T Therapy Market Forecast, 2024-2034 (US$ Million, AGR %, CAGR %)
Table 43 France CAR-T Therapy Market Forecast, 2024-2034 (US$ Million, AGR %, CAGR %)
Table 44 Italy CAR-T Therapy Market Forecast, 2024-2034 (US$ Million, AGR %, CAGR %)
Table 45 Spain CAR-T Therapy Market Forecast, 2024-2034 (US$ Million, AGR %, CAGR %)
Table 46 Rest of Europe CAR-T Therapy Market Forecast, 2024-2034 (US$ Million, AGR %, CAGR %)
Table 47 Asia Pacific CAR-T Therapy Market Forecast by Country, 2024-2034 (US$ Million, AGR %)
Table 48 Asia Pacific CAR-T Therapy Market Forecast by Target Antigens, 2024-2034 (US$ Million, AGR %)
Table 49 Asia Pacific CAR-T Therapy Market Forecast by Type, 2024-2034 (US$ Million, AGR %)
Table 50 Asia Pacific CAR-T Therapy Market Forecast by Indication, 2024-2034 (US$ Million, AGR %)
Table 51 Asia Pacific CAR-T Therapy Market Forecast by End-users, 2024-2034 (US$ Million, AGR %)
Table 52 Asia Pacific CAR-T Therapy Market Forecast by Patients, 2024-2034 (US$ Million, AGR %)
Table 53 China CAR-T Therapy Market Forecast, 2024-2034 (US$ Million, AGR %, CAGR %)
Table 54 Japan CAR-T Therapy Market Forecast, 2024-2034 (US$ Million, AGR %, CAGR %)
Table 55 Singapore CAR-T Therapy Market Forecast, 2024-2034 (US$ Million, AGR %, CAGR %)
Table 56 Australia CAR-T Therapy Market Forecast, 2024-2034 (US$ Million, AGR %, CAGR %)
Table 57 South Korea CAR-T Therapy Market Forecast, 2024-2034 (US$ Million, AGR %, CAGR %)
Table 58 Rest of Asia Pacific CAR-T Therapy Market Forecast, 2024-2034 (US$ Million, AGR %, CAGR %)
Table 59 Latin America CAR-T Therapy Market Forecast by Country, 2024-2034 (US$ Million, AGR %)
Table 60 Latin America CAR-T Therapy Market Forecast by Target Antigens, 2024-2034 (US$ Million, AGR %)
Table 61 Latin America CAR-T Therapy Market Forecast by Type, 2024-2034 (US$ Million, AGR %)
Table 62 Latin America CAR-T Therapy Market Forecast by Indication, 2024-2034 (US$ Million, AGR %)
Table 63 Latin America CAR-T Therapy Market Forecast by End-users, 2024-2034 (US$ Million, AGR %)
Table 64 Latin America CAR-T Therapy Market Forecast by Patients, 2024-2034 (US$ Million, AGR %)
Table 65 Brazil CAR-T Therapy Market Forecast, 2024-2034 (US$ Million, AGR %, CAGR %)
Table 66 Mexico CAR-T Therapy Market Forecast, 2024-2034 (US$ Million, AGR %, CAGR %)
Table 67 Rest of Latin America CAR-T Therapy Market Forecast, 2024-2034 (US$ Million, AGR %, CAGR %)
Table 68 MEA CAR-T Therapy Market Forecast by Country, 2024-2034 (US$ Million, AGR %)
Table 69 MEA CAR-T Therapy Market Forecast by Target Antigens, 2024-2034 (US$ Million, AGR %)
Table 70 MEA CAR-T Therapy Market Forecast by Type, 2024-2034 (US$ Million, AGR %)
Table 71 MEA CAR-T Therapy Market Forecast by Indication, 2024-2034 (US$ Million, AGR %)
Table 72 MEA CAR-T Therapy Market Forecast by End-users, 2024-2034 (US$ Million, AGR %)
Table 73 MEA CAR-T Therapy Market Forecast by Patients, 2024-2034 (US$ Million, AGR %)
Table 74 Israel CAR-T Therapy Market Forecast, 2024-2034 (US$ Million, AGR %, CAGR %)
Table 75 GCC CAR-T Therapy Market Forecast, 2024-2034 (US$ Million, AGR %, CAGR %)
Table 76 Rest of MEA CAR-T Therapy Market Forecast, 2024-2034 (US$ Million, AGR %, CAGR %)
Table 77 Strategic Outlook
Table 78 Gilead Sciences Inc.: Key Details (CEO, H.Q., Revenue, Founded, No. of Employees, Company Type, Website, Business Segment)
Table 79 Gilead Sciences Inc.: Product Benchmarking
Table 80 Gilead Sciences Inc.: Strategic Outlook
Table 81 Novartis AG: Key Details (CEO, H.Q., Revenue, Founded, No. of Employees, Company Type, Website, Business Segment)
Table 82 Novartis AG: Product Benchmarking
Table 83 Novartis AG: Strategic Outlook
Table 84 Bristol Myers Squibb: Key Details (CEO, H.Q., Revenue, Founded, No. of Employees, Company Type, Website, Business Segment)
Table 85 Bristol Myers Squibb: Product Benchmarking
Table 86 Bristol Myers Squibb: Strategic Outlook
Table 87 Johnson & Johnson Services, Inc.: Key Details (CEO, H.Q., Revenue, Founded, No. of Employees, Company Type, Website, Business Segment)
Table 88 Johnson & Johnson Services, Inc.: Product Benchmarking
Table 89 AbbVie Inc.: Key Details (CEO, H.Q., Revenue, Founded, No. of Employees, Company Type, Website, Business Segment)
Table 90 AbbVie Inc.: Product Benchmarking
Table 91 AbbVie Inc.: Strategic Outlook
Table 92 Amgen Inc.: Key Details (CEO, H.Q., Revenue, Founded, No. of Employees, Company Type, Website, Business Segment)
Table 93 Amgen Inc.: Product Benchmarking
Table 94 BioNTech S.E.: Key Details (CEO, H.Q., Revenue, Founded, No. of Employees, Company Type, Website, Business Segment)
Table 95 BioNTech SE: Product Benchmarking
Table 96 Bluebird bio, Inc.: Key Details (CEO, H.Q., Revenue, Founded, No. of Employees, Company Type, Website, Business Segment)
Table 97 Bluebird bio, Inc..: Product Benchmarking
Table 98 Caribou Biosciences Inc.: Key Details (CEO, H.Q., Revenue, Founded, No. of Employees, Company Type, Website, Business Segment)
Table 99 Caribou Biosciences Inc.: Product Benchmarking
Table 100 Caribou Biosciences Inc.: Strategic Outlook
Table 101 GSK plc: Key Details (CEO, H.Q., Revenue, Founded, No. of Employees, Company Type, Website, Business Segment)
Table 102 GSK plc: Product Benchmarking
Table 103 CARsgen Therapeutics Holdings Limited: Key Details (CEO, H.Q., Revenue, Founded, No. of Employees, Company Type, Website, Business Segment)
Table 104 CARsgen Therapeutics Holdings Limited: Product Benchmarking
Table 105 CARsgen Therapeutics Holdings Limited: Strategic Outlook
Table 106 Pfizer Inc.: Key Details (CEO, H.Q., Revenue, Founded, No. of Employees, Company Type, Website, Business Segment)
Table 107 Pfizer Inc.: Product Benchmarking
Table 108 Pfizer Inc.: Strategic Outlook
Table 109 Autolus Therapeutics: Key Details (CEO, H.Q., Revenue, Founded, No. of Employees, Company Type, Website, Business Segment)
Table 110 Autolus Therapeutics: Product Benchmarking
Table 111 Autolus Therapeutics: Strategic Outlook
Table 112 Intellia Therapeutics: Key Details (CEO, H.Q., Revenue, Founded, No. of Employees, Company Type, Website, Business Segment)
Table 113 Intellia Therapeutics: Product Benchmarking
Table 114 Intellia Therapeutics: Strategic Outlook
Table 115 2seventy bio, Inc.: Key Details (CEO, H.Q., Revenue, Founded, No. of Employees, Company Type, Website, Business Segment)
Table 116 2seventy bio, Inc.: Product Benchmarking
Table 117 2seventy bio, Inc.: Strategic Outlook
?

List of Figures
Figure 1 CAR-T Therapy Market Segmentation
Figure 2 CAR-T Therapy Market by Target Antigens: Market Attractiveness Index
Figure 3 CAR-T Therapy Market by Type: Market Attractiveness Index
Figure 4 CAR-T Therapy Market by Indication: Market Attractiveness Index
Figure 5 CAR-T Therapy Market by End-users: Market Attractiveness Index
Figure 6 CAR-T Therapy Market by Patient: Market Attractiveness Index
Figure 7 CAR-T Therapy Market Attractiveness Index by Region
Figure 8 CAR-T Therapy Market: Market Dynamics
Figure 9 CAR-T Therapy Market: Impact Analysis
Figure 10 CAR-T Therapy: Supply Chain Analysis
Figure 11 PEST Analysis of the CAR-T Therapy Market
Figure 12 CAR-T Therapy Market by Target Antigens: Market Attractiveness Index
Figure 13 CAR-T Therapy Market Forecast by Target Antigens, 2024-2034 (US$ Million, AGR %)
Figure 14 CAR-T Therapy Market Share Forecast by Target Antigens, 2024, 2029, 2034 (%)
Figure 15 CD19/CD22 Segment Market Forecast by Region, 2024-2034 (US$ Million, AGR %)
Figure 16 CD19/CD22 Segment Market Share Forecast by Region, 2024 & 2034 (%)
Figure 17 BCMA Segment Market Forecast by Region, 2024-2034 (US$ Million, AGR %)
Figure 18 BCMA Segment Market Share Forecast by Region, 2024 & 2034 (%)
Figure 19 Others Segment Market Forecast by Region, 2024-2034 (US$ Million, AGR %)
Figure 20 Others Segment Market Share Forecast by Region, 2024 & 2034 (%)
Figure 21 CAR-T Therapy Market by Type: Market Attractiveness Index
Figure 22 CAR-T Therapy Market Forecast by Type, 2024-2034 (US$ Million, AGR %)
Figure 23 CAR-T Therapy Market Share Forecast by Type, 2024, 2029, 2034 (%)
Figure 24 Abecma Segment Market Forecast by Region, 2024-2034 (US$ Million, AGR %)
Figure 25 Abecma Segment Market Share Forecast by Region, 2024 & 2034 (%)
Figure 26 Yescarta Segment Market Forecast by Region, 2024-2034 (US$ Million, AGR %)
Figure 27 Yescarta Segment Market Share Forecast by Region, 2024 & 2034 (%)
Figure 28 Kymriah Segment Market Forecast by Region, 2024-2034 (US$ Million, AGR %)
Figure 29 Kymriah Segment Market Share Forecast by Region, 2024 & 2034 (%)
Figure 30 Tecartus Segment Market Forecast by Region, 2024-2034 (US$ Million, AGR %)
Figure 31 Tecartus Segment Market Share Forecast by Region, 2024 & 2034 (%)
Figure 32 Other Types Segment Market Forecast by Region, 2024-2034 (US$ Million, AGR %)
Figure 33 Other Types Segment Market Share Forecast by Region, 2024 & 2034 (%)
Figure 34 Companion Diagnostics Market by Indication: Market Attractiveness Index
Figure 35 CAR-T Therapy Market Forecast by Indication, 2024-2034 (US$ Million, AGR %)
Figure 36 Companion Diagnostics Market Share Forecast by Indication, 2024, 2029, 2034 (%)
Figure 37 Diffuse Large B-Cell Lymphoma (DLBCL) Segment Market Forecast by Region, 2024-2034 (US$ Million, AGR %)
Figure 38 Diffuse Large B-Cell Lymphoma (DLBCL) Segment Market Share Forecast by Region, 2024 & 2034 (%)
Figure 39 Acute Lymphoblastic Leukaemia (ALL) Segment Market Forecast by Region, 2024-2034 (US$ Million, AGR %)
Figure 40 Acute Lymphoblastic Leukaemia (ALL) Segment Market Share Forecast by Region, 2024 & 2034 (%)
Figure 41 Follicular Lymphoma Segment Market Forecast by Region, 2024-2034 (US$ Million, AGR %)
Figure 42 Follicular Lymphoma Segment Market Share Forecast by Region, 2024 & 2034 (%)
Figure 43 Multiple Myeloma (MM) Segment Market Forecast by Region, 2024-2034 (US$ Million, AGR %)
Figure 44 Multiple Myeloma (MM) Segment Market Share Forecast by Region, 2024 & 2034 (%)
Figure 45 Other Indication Segment Market Forecast by Region, 2024-2034 (US$ Million, AGR %)
Figure 46 Other Indication Segment Market Share Forecast by Region, 2024 & 2034 (%)
Figure 47 CAR-T Therapy Market by End-users: Market Attractiveness Index
Figure 48 CAR-T Therapy Market Forecast by End-users, 2024-2034 (US$ Million, AGR %)
Figure 49 CAR-T Therapy Market Share Forecast by End-users, 2024, 2029, 2034 (%)
Figure 50 Hospitals Segment Market Forecast by Region, 2024-2034 (US$ Million, AGR %)
Figure 51 Hospitals Segment Market Share Forecast by Region, 2024 & 2034 (%)
Figure 52 Specialty Clinics Segment Market Forecast by Region, 2024-2034 (US$ Million, AGR %)
Figure 53 Specialty Clinics Segment Market Share Forecast by Region, 2024 & 2034 (%)
Figure 54 Other End-users Segment Market Forecast by Region, 2024-2034 (US$ Million, AGR %)
Figure 55 Other End-users Segment Market Share Forecast by Region, 2024 & 2034 (%)
Figure 56 CAR-T Therapy Market by Patient: Market Attractiveness Index
Figure 57 CAR-T Therapy Market Forecast by Patient, 2024-2034 (US$ Million, AGR %)
Figure 58 CAR-T Therapy Market Share Forecast by Patient, 2024, 2029, 2034 (%)
Figure 59 Children Segment Market Forecast by Region, 2024-2034 (US$ Million, AGR %)
Figure 60 Children Segment Market Share Forecast by Region, 2024 & 2034 (%)
Figure 61 Adults Segment Market Forecast by Region, 2024-2034 (US$ Million, AGR %)
Figure 62 Adults Segment Market Share Forecast by Region, 2024 & 2034 (%)
Figure 63 Seniors Segment Market Forecast by Region, 2024-2034 (US$ Million, AGR %)
Figure 64 Seniors Segment Market Share Forecast by Region, 2024 & 2034 (%)
Figure 65 CAR-T Therapy Market Forecast by Region 2024 and 2034 (Revenue, CAGR%)
Figure 66 CAR-T Therapy Market Share Forecast by Region 2024, 2029, 2034 (%)
Figure 67 CAR-T Therapy Market by Region, 2024-2034 (US$ Million, AGR %)
Figure 68 North America CAR-T Therapy Market Attractiveness Index
Figure 69 North America CAR-T Therapy Market by Region, 2024, 2029 & 2034 (US$ Million)
Figure 70 North America CAR-T Therapy Market Forecast by Country, 2024-2034 (US$ Million, AGR %)
Figure 71 North America CAR-T Therapy Market Share Forecast by Country, 2024 & 2034 (%)
Figure 72 North America CAR-T Therapy Market Forecast by Target Antigens, 2024-2034 (US$ Million, AGR %)
Figure 73 North America CAR-T Therapy Market Share Forecast by Target Antigens, 2024 & 2034 (%)
Figure 74 North America CAR-T Therapy Market Forecast by Type, 2024-2034 (US$ Million, AGR %)
Figure 75 North America CAR-T Therapy Market Share Forecast by Type, 2024 & 2034 (%)
Figure 76 North America CAR-T Therapy Market Forecast by Indication, 2024-2034 (US$ Million, AGR %)
Figure 77 North America CAR-T Therapy Market Share Forecast by Indication, 2024 & 2034 (%)
Figure 78 North America CAR-T Therapy Market Forecast by End-users, 2024-2034 (US$ Million, AGR %)
Figure 79 North America CAR-T Therapy Market Share Forecast by End-users, 2024 & 2034 (%)
Figure 80 North America CAR-T Therapy Market Forecast by Patients, 2024-2034 (US$ Million, AGR %)
Figure 81 North America CAR-T Therapy Market Share Forecast by Patients, 2024 & 2034 (%)
Figure 82 U.S. CAR-T Therapy Market Forecast, 2024-2034 (US$ Million, AGR %)
Figure 83 Canada CAR-T Therapy Market Forecast, 2024-2034 (US$ Million, AGR %)
Figure 84 Europe CAR-T Therapy Market Attractiveness Index
Figure 85 Europe CAR-T Therapy Market by Region, 2024, 2029 & 2034 (US$ Million)
Figure 86 Europe CAR-T Therapy Market Forecast by Country, 2024-2034 (US$ Million, AGR %)
Figure 87 Europe CAR-T Therapy Market Share Forecast by Country, 2024 & 2034 (%)
Figure 88 Europe CAR-T Therapy Market Forecast by Target Antigens, 2024-2034 (US$ Million, AGR %)
Figure 89 Europe CAR-T Therapy Market Share Forecast by Target Antigens, 2024 & 2034 (%)
Figure 90 Europe CAR-T Therapy Market Forecast by Type, 2024-2034 (US$ Million, AGR %)
Figure 91 Europe CAR-T Therapy Market Share Forecast by Type, 2024 & 2034 (%)
Figure 92 Europe CAR-T Therapy Market Forecast by Indication, 2024-2034 (US$ Million, AGR %)
Figure 93 Europe CAR-T Therapy Market Share Forecast by Indication, 2024 & 2034 (%)
Figure 94 Europe CAR-T Therapy Market Forecast by End-user, 2024-2034 (US$ Million, AGR %)
Figure 95 Europe CAR-T Therapy Market Share Forecast by End-user, 2024 & 2034 (%)
Figure 96 Europe CAR-T Therapy Market Forecast by Patients, 2024-2034 (US$ Million, AGR %)
Figure 97 Europe CAR-T Therapy Market Share Forecast by Patients, 2024 & 2034 (%)
Figure 98 Germany CAR-T Therapy Market Forecast, 2024-2034 (US$ Million, AGR %)
Figure 99 UK CAR-T Therapy Market Forecast, 2024-2034 (US$ Million, AGR %)
Figure 100 France CAR-T Therapy Market Forecast, 2024-2034 (US$ Million, AGR %)
Figure 101 Italy CAR-T Therapy Market Forecast, 2024-2034 (US$ Million, AGR %)
Figure 102 Spain CAR-T Therapy Market Forecast, 2024-2034 (US$ Million, AGR %)
Figure 103 Rest of Europe CAR-T Therapy Market Forecast, 2024-2034 (US$ Million, AGR %)
Figure 104 Asia Pacific CAR-T Therapy Market Attractiveness Index
Figure 105 Asia Pacific CAR-T Therapy Market by Region, 2024, 2029 & 2034 (US$ Million)
Figure 106 Asia Pacific CAR-T Therapy Market Forecast by Country, 2024-2034 (US$ Million, AGR %)
Figure 107 Asia Pacific CAR-T Therapy Market Share Forecast by Country, 2024 & 2034 (%)
Figure 108 Asia Pacific CAR-T Therapy Market Forecast by Target Antigens, 2024-2034 (US$ Million, AGR %)
Figure 109 Asia Pacific CAR-T Therapy Market Share Forecast by Target Antigens, 2024 & 2034 (%)
Figure 110 Asia Pacific CAR-T Therapy Market Forecast by Type, 2024-2034 (US$ Million, AGR %)
Figure 111 Asia Pacific CAR-T Therapy Market Share Forecast by Type, 2024 & 2034 (%)
Figure 112 Asia Pacific CAR-T Therapy Market Forecast by Indication, 2024-2034 (US$ Million, AGR %)
Figure 113 Asia Pacific CAR-T Therapy Market Share Forecast by Indication, 2024 & 2034 (%)
Figure 114 Asia Pacific CAR-T Therapy Market Forecast by End-users, 2024-2034 (US$ Million, AGR %)
Figure 115 Asia Pacific CAR-T Therapy Market Share Forecast by End-users, 2024 & 2034 (%)
Figure 116 Asia Pacific CAR-T Therapy Market Forecast by Patients, 2024-2034 (US$ Million, AGR %)
Figure 117 Asia Pacific CAR-T Therapy Market Share Forecast by Patients, 2024 & 2034 (%)
Figure 118 China CAR-T Therapy Market Forecast, 2024-2034 (US$ Million, AGR %)
Figure 119 Japan CAR-T Therapy Market Forecast, 2024-2034 (US$ Million, AGR %)
Figure 120 Singapore CAR-T Therapy Market Forecast, 2024-2034 (US$ Million, AGR %)
Figure 121 Australia CAR-T Therapy Market Forecast, 2024-2034 (US$ Million, AGR %)
Figure 122 South Korea CAR-T Therapy Market Forecast, 2024-2034 (US$ Million, AGR %)
Figure 123 Rest of Asia Pacific CAR-T Therapy Market Forecast, 2024-2034 (US$ Million, AGR %)
Figure 124 Latin America CAR-T Therapy Market Attractiveness Index
Figure 125 Latin America CAR-T Therapy Market by Region, 2024, 2029 & 2034 (US$ Million)
Figure 126 Latin America CAR-T Therapy Market Forecast by Country, 2024-2034 (US$ Million, AGR %)
Figure 127 Latin America CAR-T Therapy Market Share Forecast by Country, 2024 & 2034 (%)
Figure 128 Latin America CAR-T Therapy Market Forecast by Target Antigens, 2024-2034 (US$ Million, AGR %)
Figure 129 Latin America CAR-T Therapy Market Share Forecast by Target Antigens, 2024 & 2034 (%)
Figure 130 Latin America CAR-T Therapy Market Forecast by Type, 2024-2034 (US$ Million, AGR %)
Figure 131 Latin America CAR-T Therapy Market Share Forecast by Type, 2024 & 2034 (%)
Figure 132 Latin America CAR-T Therapy Market Forecast by Indication, 2024-2034 (US$ Million, AGR %)
Figure 133 Latin America CAR-T Therapy Market Share Forecast by Indication, 2024 & 2034 (%)
Figure 134 Latin America CAR-T Therapy Market Forecast by End-users, 2024-2034 (US$ Million, AGR %)
Figure 135 Latin America CAR-T Therapy Market Share Forecast by End-users, 2024 & 2034 (%)
Figure 136 Latin America CAR-T Therapy Market Forecast by Patients, 2024-2034 (US$ Million, AGR %)
Figure 137 Latin America CAR-T Therapy Market Share Forecast by Patients, 2024 & 2034 (%)
Figure 138 Brazil CAR-T Therapy Market Forecast, 2024-2034 (US$ Million, AGR %)
Figure 139 Mexico CAR-T Therapy Market Forecast, 2024-2034 (US$ Million, AGR %)
Figure 140 Rest of Latin America CAR-T Therapy Market Forecast, 2024-2034 (US$ Million, AGR %)
Figure 141 MEA CAR-T Therapy Market Attractiveness Index
Figure 142 MEA CAR-T Therapy Market by Region, 2024, 2029 & 2034 (US$ Million)
Figure 143 MEA CAR-T Therapy Market Forecast by Country, 2024-2034 (US$ Million, AGR %)
Figure 144 MEA CAR-T Therapy Market Share Forecast by Country, 2024 & 2034 (%)
Figure 145 MEA CAR-T Therapy Market Forecast by Target Antigens, 2024-2034 (US$ Million, AGR %)
Figure 146 MEA CAR-T Therapy Market Share Forecast by Target Antigens, 2024 & 2034 (%)
Figure 147 MEA CAR-T Therapy Market Forecast by Type, 2024-2034 (US$ Million, AGR %)
Figure 148 MEA CAR-T Therapy Market Share Forecast by Type, 2024 & 2034 (%)
Figure 149 MEA CAR-T Therapy Market Forecast by Indication, 2024-2034 (US$ Million, AGR %)
Figure 150 MEA CAR-T Therapy Market Share Forecast by Indication, 2024 & 2034 (%)
Figure 151 MEA CAR-T Therapy Market Forecast by End-users, 2024-2034 (US$ Million, AGR %)
Figure 152 MEA CAR-T Therapy Market Share Forecast by End-users, 2024 & 2034 (%)
Figure 153 MEA CAR-T Therapy Market Forecast by Patients, 2024-2034 (US$ Million, AGR %)
Figure 154 Middle East & Africa CAR-T Therapy Market Share Forecast by Patients, 2024 & 2034 (%)
Figure 155 Israel CAR-T Therapy Market Forecast, 2024-2034 (US$ Million, AGR %)
Figure 156 GCC CAR-T Therapy Market Forecast, 2024-2034 (US$ Million, AGR %)
Figure 157 Rest of MEA CAR-T Therapy Market Forecast, 2024-2034 (US$ Million, AGR %)
Figure 158 CAR-T Therapy Market: Company Share/Ranking, 2023
Figure 159 Gilead Sciences Inc.: Net Revenue, 2018-2023 (US$ Million, AGR%)
Figure 160 Gilead Sciences Inc.: R&D, 2018-2023 (US$ Million, AGR%)
Figure 161 Gilead Sciences Inc.: Regional Market Shares, 2023
Figure 162 Gilead Sciences Inc.: SWOT Analysis
Figure 163 Novartis AG: Net Revenue, 2018-2023 (US$ Million, AGR%)
Figure 164 Novartis AG: R&D, 2018-2023 (US$ Million, AGR%)
Figure 165 Novartis AG: Regional Market Shares, 2023
Figure 166 Novartis AG: SWOT Analysis
Figure 167 Bristol Myers Squibb: Net Revenue, 2018-2023 (US$ Million, AGR%)
Figure 168 Bristol Myers Squibb: R&D, 20180-2023 (US$ Million, AGR%)
Figure 169 Bristol Myers Squibb: Regional Market Shares, 2023
Figure 170 Bristol Myers Squibb: SWOT Analysis
Figure 171 Johnson & Johnson (J&J): Net Revenue, 2017-2022 (US$ Million, AGR%)
Figure 172 Johnson & Johnson (J&J): R&D, 2017-2022 (US$ Million, AGR%)
Figure 173 Johnson & Johnson (J&J): Regional Market Shares, 2022
Figure 174 Johnson & Johnson Services, Inc.: SWOT Analysis
Figure 175 AbbVie Inc.: Net Revenue, 2018-2023 (US$ Million, AGR%)
Figure 176 AbbVie Inc.: R&D, 2018-2023 (US$ Million, AGR%)
Figure 177 AbbVie Inc.: Regional Market Shares, 2023
Figure 178 Amgen Inc.: Net Revenue, 2018-2023 (US$ Million, AGR%)
Figure 179 Amgen Inc.: R&D, 2018-2023 (US$ Million, AGR%)
Figure 180 Amgen Inc.: Regional Market Shares, 2023
Figure 181 BioNTech S.E.: Net Revenue, 2018-2023 (US$ Million, AGR%)
Figure 182 BioNTech S.E.: R&D, 2018-2023 (US$ Million, AGR%)
Figure 183 Bluebird bio, Inc.: Net Revenue, 2017-2022 (US$ Million, AGR%)
Figure 184 Bluebird bio, Inc.: R&D, 2017-2022 (US$ Million, AGR%)
Figure 185 Caribou Biosciences, Inc.: Net Revenue, 2019-2023 (US$ Million, AGR%)
Figure 186 Caribou Biosciences, Inc.: R&D, 2019-2023 (US$ Million, AGR%)
Figure 187 GSK plc: Net Revenue, 2018-2023 (US$ Million, AGR%)
Figure 188 GSK plc: R&D, 2018-2023 (US$ Million, AGR%)
Figure 189 GSK plc: Regional Market Shares, 2023
Figure 190 Pfizer: Net Revenue, 2018-2023 (US$ Million, AGR%)
Figure 191 Pfizer: R&D, 2018-2023 (US$ Million, AGR%)
Figure 192 Pfizer: Regional Market Shares, 2023

この商品のレポートナンバー

0000038611

TOP